{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:51Z","timestamp":1792440591140,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00228-010-0893-3","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T10:31:34Z","timestamp":1284978694000},"page":"63-71","source":"Crossref","is-referenced-by-count":68,"title":["Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone"],"prefix":"10.1007","volume":"67","author":[{"given":"Oliver","family":"Kummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Drewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"893_CR1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00520-002-0385-9","volume":"11","author":"MP Davis","year":"2003","unstructured":"Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84\u201392","journal-title":"Support Care Cancer"},{"key":"893_CR2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1399-6576.1986.tb02487.x","volume":"30","author":"LS Nuutinen","year":"1986","unstructured":"Nuutinen LS, Wuolijoki E, Pentikainen IT (1986) Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial. Acta Anaesthesiol Scand 30:620\u2013624","journal-title":"Acta Anaesthesiol Scand"},{"key":"893_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0885-3924(98)00064-5","volume":"16","author":"WC Parris","year":"1998","unstructured":"Parris WC, Johnson BW Jr, Croghan MK et al (1998) The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 16:205\u2013211","journal-title":"J Pain Symptom Manage"},{"key":"893_CR4","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.1998.16.10.3222","volume":"16","author":"E Bruera","year":"1998","unstructured":"Bruera E, Belzile M, Pituskin E et al (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222\u20133229","journal-title":"J Clin Oncol"},{"key":"893_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002280050651","volume":"55","author":"GB Curtis","year":"1999","unstructured":"Curtis GB, Johnson GH, Clark P et al (1999) Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55:425\u2013429","journal-title":"Eur J Clin Pharmacol"},{"key":"893_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","volume":"8","author":"M Kirvela","year":"1996","unstructured":"Kirvela M, Lindgren L, Seppala T, Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13\u201318","journal-title":"J Clin Anesth"},{"key":"893_CR7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","volume":"32","author":"B Lalovic","year":"2004","unstructured":"Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447\u2013454","journal-title":"Drug Metab Dispos"},{"key":"893_CR8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","volume":"18","author":"CE Inturrisi","year":"2002","unstructured":"Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:S3\u2013S13","journal-title":"Clin J Pain"},{"key":"893_CR9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","volume":"64","author":"T Heiskanen","year":"1998","unstructured":"Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603\u2013611","journal-title":"Clin Pharmacol Ther"},{"key":"893_CR10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461\u2013479","journal-title":"Clin Pharmacol Ther"},{"key":"893_CR11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1742-7843.2009.00378.x","volume":"104","author":"ST Zwisler","year":"2009","unstructured":"Zwisler ST, Enggaard TP, Noehr-Jensen L et al (2009) The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104:335\u2013344","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"893_CR12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","volume":"54","author":"ST Zwisler","year":"2010","unstructured":"Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 54:232\u2013240","journal-title":"Acta Anaesthesiol Scand"},{"key":"893_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","volume":"65","author":"NM Hagelberg","year":"2009","unstructured":"Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65:263\u2013271","journal-title":"Eur J Clin Pharmacol"},{"key":"893_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0091270009336444","volume":"50","author":"J Gronlund","year":"2010","unstructured":"Gronlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, Olkkola KT, Laine K (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 50:101\u2013108","journal-title":"J Clin Pharmacol"},{"key":"893_CR15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0b013e31819faa54","volume":"110","author":"TH Nieminen","year":"2009","unstructured":"Nieminen TH, Hagelberg NM, Saari TI et al (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110:1371\u20131378","journal-title":"Anesthesiology"},{"key":"893_CR16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.clpt.2004.11.002","volume":"77","author":"S Laugesen","year":"2005","unstructured":"Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312\u2013323","journal-title":"Clin Pharmacol Ther"},{"key":"893_CR17","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1373\/49.10.1624","volume":"49","author":"B M\u00fcller","year":"2003","unstructured":"M\u00fcller B, Zopf K, Bachofer J, Steimer W (2003) Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 49:1624\u20131631","journal-title":"Clin Chem"},{"key":"893_CR18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.2003.02049.x","volume":"57","author":"M Wenk","year":"2004","unstructured":"Wenk M, Todesco L, Krahenbuhl S (2004) Effect of St John\u2019s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 57:495\u2013499","journal-title":"Br J Clin Pharmacol"},{"key":"893_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FTD.0b013e31816e2d4b","volume":"30","author":"M Neuvonen","year":"2008","unstructured":"Neuvonen M, Neuvonen PJ (2008) Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Ther Drug Monit 30:333\u2013340","journal-title":"Ther Drug Monit"},{"key":"893_CR20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2125.2007.03035.x","volume":"64","author":"L Haegeli","year":"2007","unstructured":"Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S (2007) Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol 64:804\u2013809","journal-title":"Br J Clin Pharmacol"},{"key":"893_CR21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/ac60214a047","volume":"36","author":"A Savitzky","year":"2002","unstructured":"Savitzky A, Golay MJE (2002) Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 36:1627\u20131639","journal-title":"Anal Chem"},{"key":"893_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5055\/jom.2007.0008","volume":"3","author":"E Eisenberg","year":"2007","unstructured":"Eisenberg E, Cohen D, Lawental E, Pud D (2007) Personality traits and sensitivity to pain in male chronic opioid addicts. J Opioid Manag 3:225\u2013230","journal-title":"J Opioid Manag"},{"key":"893_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.2010.03653.x","volume":"70","author":"J Gr\u00f6nlund","year":"2010","unstructured":"Gr\u00f6nlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70:78\u201387","journal-title":"Br J Clin Pharmacol"},{"key":"893_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.sjpain.2009.09.003","volume":"1","author":"KK Lemberg","year":"2010","unstructured":"Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, Kalso EA (2010) Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand J Pain 1:24\u201333","journal-title":"Scand J Pain"},{"key":"893_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1989.tb07161.x","volume":"350","author":"AM Johnson","year":"1989","unstructured":"Johnson AM (1989) An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl 350:14\u201320","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"893_CR26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004583-200002000-00006","volume":"39","author":"M Larson","year":"2000","unstructured":"Larson M, Folstein S (2000) Selective serotonin reuptake inhibitor-induced mydriasis. J Am Acad Child Adolesc Psychiatry 39:138\u2013139","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"893_CR27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-001-0993-y","volume":"160","author":"JA Schmitt","year":"2002","unstructured":"Schmitt JA, Riedel WJ, Vuurman EF, Kruizinga M, Ramaekers JG (2002) Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 160:381\u2013386","journal-title":"Psychopharmacology (Berl)"},{"key":"893_CR28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1213\/01.ANE.0000116924.16535.BA","volume":"99","author":"RD Knaggs","year":"2004","unstructured":"Knaggs RD, Crighton IM, Cobby TF, Fletcher AJ, Hobbs GJ (2004) The pupillary effects of intravenous morphine, codeine, and tramadol in volunteers. Anesth Analg 99:108\u2013112","journal-title":"Anesth Analg"},{"key":"893_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0024-3205(83)90123-6","volume":"33","author":"RB Murray","year":"1983","unstructured":"Murray RB, Adler MW, Korczyn AD (1983) The pupillary effects of opioids. Life Sci 33:495\u2013509","journal-title":"Life Sci"},{"key":"893_CR30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0022-3565(25)30077-7","volume":"192","author":"HK Lee","year":"1975","unstructured":"Lee HK, Wang SC (1975) Mechanism of morphine-induced miosis in the dog. J Pharmacol Exp Ther 192:415\u2013431","journal-title":"J Pharmacol Exp Ther"},{"key":"893_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(96)00693-0","volume":"317","author":"MR Prow","year":"1996","unstructured":"Prow MR, Martin KF, Heal DJ (1996) 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation. Eur J Pharmacol 317:21\u201328","journal-title":"Eur J Pharmacol"},{"key":"893_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1254\/jphs.94.161","volume":"94","author":"EN Duman","year":"2004","unstructured":"Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N (2004) Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 94:161\u2013165","journal-title":"J Pharmacol Sci"},{"key":"893_CR33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/jphs.FP0040153","volume":"97","author":"M Kesim","year":"2005","unstructured":"Kesim M, Duman EN, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N (2005) The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice. J Pharmacol Sci 97:61\u201366","journal-title":"J Pharmacol Sci"},{"key":"893_CR34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0006-8993(01)02854-2","volume":"915","author":"VP Singh","year":"2001","unstructured":"Singh VP, Jain NK, Kulkarni SK (2001) On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 915:218\u2013226","journal-title":"Brain Res"},{"key":"893_CR35","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/009127000004001114","volume":"40","author":"MK Erjavec","year":"2000","unstructured":"Erjavec MK, Coda BA, Nguyen Q, Donaldson G, Risler L, Shen DD (2000) Morphine-fluoxetine interactions in healthy volunteers: analgesia and side effects. J Clin Pharmacol 40:1286\u20131295","journal-title":"J Clin Pharmacol"},{"key":"893_CR36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3959(94)90187-2","volume":"58","author":"NC Gordon","year":"1994","unstructured":"Gordon NC, Heller PH, Gear RW, Levine JD (1994) Interactions between fluoxetine and opiate analgesia for postoperative dental pain. Pain 58:85\u201388","journal-title":"Pain"},{"key":"893_CR37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CP, Bertolini A, Sternieri E (2004) Methadone\u2014metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551\u2013559","journal-title":"Pharmacol Res"},{"key":"893_CR38","first-page":"167","volume":"82","author":"T Tateishi","year":"1996","unstructured":"Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82:167\u2013172","journal-title":"Anesth Analg"},{"key":"893_CR39","first-page":"818","volume":"26","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y (1998) Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26:818\u2013821","journal-title":"Drug Metab Dispos"},{"key":"893_CR40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/03602530701690374","volume":"39","author":"YT Liu","year":"2007","unstructured":"Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG (2007) Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 39:699\u2013721","journal-title":"Drug Metab Rev"},{"key":"893_CR41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","volume":"66","author":"B Link","year":"2008","unstructured":"Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krahenbuhl S (2008) Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol 66:473\u2013484","journal-title":"Br J Clin Pharmacol"},{"key":"893_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","volume":"7","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257\u2013265","journal-title":"Pharmacogenomics J"},{"key":"893_CR43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","volume":"368","author":"G Koren","year":"2006","unstructured":"Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368:704","journal-title":"Lancet"},{"key":"893_CR44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1213\/ane.0b013e31817b796e","volume":"107","author":"UM Stamer","year":"2008","unstructured":"Stamer UM, Stuber F, Muders T, Musshoff F (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107:926\u2013929","journal-title":"Anesth Analg"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0893-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0893-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0893-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T22:52:04Z","timestamp":1740523924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0893-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0893-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]}}}